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Rapport de Synthèse 
L'état de mal épileptique est une condition médicale sévère fréquemment rencontrée dont la 
mortalité est importante. Son traitement représente donc une urgence médicale. Il a déjà été 
démontré par des études bien conduites (Treiman et al., 1998) que l'administration de 
benzodiazépines est efficace en première intention. Or, 35-45% des états de mal échappent à ce 
traitement et malheureusement, les données scientifiques concernant le traitement de deuxième 
ligne sont nettement moins consistantes. Par ailleurs, si le rôle pronostique des caractéristiques de 
l'état de mal (type de crise, étiologie, état de conscience, âge du patient) sont connues (Rossetti et 
al., 2006), (Neligan and Shorvon, 2011), le rôle des comorbidités n'a reçu que peu d'attention à ce 
jour. 
Dans la première partie de ce travail publiée dans Epi/epsia (Alvarez et al., 2011) nous nous sommes 
intéressé au traitement de deuxième ligne et principalement aux trois substances les plus prescrites: 
la phénytoine (PHT), le valproate (VPA) et plus récemment le lévétiracetam (LEV). A ce jour, aucune 
étude n'avait comparé l'efficacité de ces substances pourtant largement utilisées. Ainsi, afin de 
savoir lequel ces anti-épileptiques utilisés en 2ème ligne est le plus efficace, nous avons extrait de 
notre base de données regroupant tout les états de mal épileptiques traités au Centre Hospitalier 
Universitaire Vaudois, tous les épisodes durant lesquelles le traitement par benzodiazépines à 
échoué (187 épisodes). Nous avons ensuite comparé les différentes caractéristiques cliniques et les 
différents outcomes de trois groupes de patients (ceux qui ont reçu de la PHT, du VPA ou du LEV). 
Nous avons pu mettre ainsi en évidence certaines différences d'efficacité inconnues jusqu'alors entre 
le VPA et le LEV, impliquant une certaine prudence face à l'emploi grandissant de ce dernier. 
La seconde partie de notre publiée dans Epi/epsia (Alvarez et al., 2012) s'est portée sur les facteurs 
pronostiques de l'état de mal et plus précisément sur le rôle joué par les comorbidités. En utilisant la 
même base de données, nous avons pu démontrer que le pronostique d'un état de mal est très 
majoritairement influencé par l'étiologie et l'âge et que les comorbidités ne jouent qu'un rôle 
marginal. La présence de comorbidités n'impliquant pas forcément une mauvaise issue, la fragilité de 
certains patients ne doit pas dissuader les cliniciens à traiter adéquatement ces patients souffrant 
d'une condition aussi sévère qu'un état de mal épileptique. 
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Second-line status epilepticus treatment: Comparison of 
phenytoin, valproate, and levetiracetam 
*Vincent Alvarez, tJean-Marie januel, tBernard Burnand, and *Andrea O. Rossetti 
*Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and Univeristy of Lausanne (UNIL), 
Lausanne, Switzerland; and tCenter ofClinical Epidemiology, lnstitute of Social and Preventive Medicine, Lausanne University 
Hospital (CHUV) and Univeristy of Lausanne (UNIL), Lausanne, Switzerland 
SuMMARY 
Purpose: Phenytoin (PHT), valproic acid (VPA), or leveti-
racetam (LEV) are commonly used as second-line treat-
ment of status epilepticus (SE), but comparative studies 
are not available. 
Methods: Among 279 adult SE episodes identified pro-
spectively in our tertiary care hospital over 4 years, we 
retrospectively identified 187 episodes in which PHT, 
VPA, or LEV were given after benzodiazepines. Patients 
with postanoxic SE were not included. Demographics, 
clinical SE features, failure of second-line treatment to 
control SE, new handicap, and mortality at hospital dis-
charge were assessed. Uni- and multivariable statistical 
analyses were applied to compare the three agents. 
Key Findings: Each compound was used in about one third 
of SE episodes. VPA failed to control SE in 25.4%, PHT in 
41.4%, and LEV in 48.3% of episodes in which these were 
Status epilepticus (SE) represents a severe condition with 
significant mortality and morbidity (Coeytaux et al., 2000; 
Knake et al., 2001; Vignatelli et al., 2003), and its timely 
treatment is indicated to prevent potentially deleterious 
complications (Lowenstein & Alldredge, 1998). Unfortu-
nately, high-level evidence is available only for the first-line 
medication; in particular, lorazepam has been shown to be 
more effective than phenytoin (PHT) or placebo (Treiman 
et al., 1998; Alldredge et al., 2001); therefore, intravenous 
benzodiazepines are recommended as an initial approach 
(Meierkord et al., 2010). However, because first-line ther-
apy fails to control at least 35-45% of patients with SE 
(Treiman et al., 1998), additional treatments are needed, for 
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prescribed. A deadly etiology was more frequent in the 
VPA group, whereas SE episodes tended to be more 
severe in the PHT group. After adjustment for these 
known SE outcome predictors, LEV failed more often 
than VPA [odds ratio (OR) 2.69; 95% confidence interval 
(Cl) 1.19-6.08]; 16.8% (95% Cl: 6.0-31.4%) of second-line 
treatment failures could be attributed to LEV. PHT was 
not statistically different from the other two compounds. 
Second-line treatment did not seem to influence new 
handicap and mortality, whereas etiology and the SE 
Severity Score (STESS) were robust independent predic-
tors. 
Significance: Even without significant differences on out-
come at discharge, LEV seems less efficient than VPA to 
control SE after benzodiazepines. A prospective compar-
ative trial is needed to address this potentially concerning 
finding. 
KEY WORDS: Epilepsy, Seizures, Intensive care neurology. 
whom convincing evidence is lacking. Historically, phenyt-
oin (PHT) (Wallis et al., 1968; Pilz & Dreyer, 1969) has 
been used before valproic acid (VP A) (Sinha & Naritoku, 
2000; Trinka, 2009) as a second-line agent. The Veterans 
Affairs study (Treiman et al., 1998) together with other 
smaller series (Misra et al., 2006; Gilad et al., 2008) 
showed that PHT is useful as first-line therapy, but compar-
ative investigations using those compounds as second-line 
treatment after benzodiazepines are very scarce. A small 
prospective randomized study (Agarwal et al., 2007) ana-
lyzed PHT and VP A after diazepam failure and showed that 
both drugs were surprisingly highly effective (controlling 
SE in 88% and 84% of patients, respectively). More 
recently, levetiracetam (LEV) (Rossetti & Bromfield, 2006; 
Knake et al., 2008) and, to a much more limited extent, la-
cosamide (Kellinghaus et al., 2011) have also been 
described for this indication, but again without any compari-
son to other agents. 
To address this relevant Jack of information, we used our 
SE database to investigate the relative role of PHT, VPA, 
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and LEV in the treatment of SE as second-line agents. We 
did not consider lacosamide, as it was marketed in Switzer-
land only in September 2009, whereas all other drugs were 
available before 2006. 
METHODS 
Patients and procedures 
We retrospectively analyzed data from a prospective reg-
istry including all patients treated atour center (tertiary hos-
pital) over 4 years for SE between April 1, 2006 and March 
31, 2010. Details on the registry were recently published in 
another study (Novy et al., 2010). Briefly, SE was defined 
as the continuous occurrence of seizures for >5 min, or 
repeated epileptic seizures without intercurrent baseline 
recovery. Seizures were diagnosed clinically, but formai 
electroencephalography (EEG) confirmation was required 
for nonconvulsive episodes. SE episodes were identified 
and screened by our neurologie consultants at the emer-
gency unit and intensive care unit, and by the EEG staff. 
Subjects younger than 16 years old and patients with pos-
tanoxic SE were not included. We indentified all SE epi-
sodes in which a second-line treatment was prescribed. 
Our protocol to treat SE starts with intravenous ben-
zodiazepines (clonazepam 0.015 mg/kg or lorazepam 
0.1 mg/kg), followed by a choice of PHT 20 mg/kg, VP A 
20 mg/kg, or LEV 20 mg/kg; all are relayed by maintenance 
dosages (typically, 300-400 mg PHT, 1,000-2,500 mg 
VPA, or 1,000-3,000 mg LEV daily). The second-line treat-
ment is typically administered within 1-30 min following 
benzodiazepines. Most of these drugs are given intrave-
nously. Every case is discussed within 48 h with one or 
both senior epileptologists of our center to guide SE treat-
ment after the application of the initial algorithm. 
Variables 
Age, gender, history of previous seizures, seizures type 
(partial vs. generalized), consciousness before treatment 
institution, treatments, and SE etiology were recorded pro-
spectively. Consciousness was categorized as alert/confuse/ 
somnolent versus stuporous/comatose. For each patient, 
a 1validated SE severity score (STESS) was calculated 
(Rossetti et al., 2008) and its scores categorized in 23 or <3 
(Table 1). Etiology was considered "deadly" if leading to 
death if not specifically treated, as described previously 
(Rossetti et al., 2006), including: massive ischemic and 
hemorrhagic stroke, primary or secondary cerebral tumor, 
central nervous system (CNS) infection, severe autoimmune 
disease, AIDS with CNS complication, and metabolic dis-
turbance sufficient to cause coma, eclampsia, and sepsis. 
We also categorized etiology as acute versus nonacute 
(Commission on Epidemiology and Prognosis, ILAE, 
1993). The primary outcome was the failure of the second-
line treatment, defined as the need to introduce a further 
compound to control SE. W e considered SE as controlled if 
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Table 1. Status Epilepticus Severity Score (STESS), 
a favorable score is 0-2 
Features STE SS 
Consciousness 
Alert or somnolent/confused 0 
Stuporous or comatose 1 
Worst seizure type 
Simple-partial, complex-partial, absence, myoclonic0 0 
Generalized-convulsive 1 
Nonconvulsive status epilepticus in coma 2 
Age 
<65 years 0 
265 years 2 
History of previous seizures 
Yes 0 
No or unknown 1 
Total 0-6 
°Complicating idiopathie generalized epilepsy. 
Adapted from Rossetti et al. (2008). 
no change in antiepileptic medication was needed for at 
least 48 h after clinical and electrographic resolution. We 
developed a specific multilevel variable to define second-
line treatment, where each compound represented one level 
of the variable (VP A being the reference, the second level 
was PHT, and the third was LEV). We also prospectively 
recorded, at hospital discharge, mortality ( calculated using 
patients instead of episodes as denominator), new handicap 
(failure to return to baseline clinical conditions), or return to 
baseline. 
Statistical analyses 
Comparisons among the three treatment groups were per-
formed using two-tailed Fisher's exact, chi-square, or analy-
sis of variance (ANOV A) tests, as required. In order to 
adjust the results for possible confounders, variables with 
p < 0.2 were entered in stepwise logistic regressions using 
the outcome as dependent variable; goodness of fit was 
evaluated using a chi-square test. The population attribut-
able fraction (PAF) of failure of the second-line treatment 
when using the worst acting agent was calculated using the 
f01mula (Miettinen, 1974; Hanley, 2001): 
(Prevalence of patients exposed to the second-line 
treatment in the failure cases) 
x ([odds ratio - l]/odds ratio) 
To perform a multivariate analysis and generate an 
adjusted estimate of the PAF of failure of the second-treat-
ment, we determined the PAF for multiple levels of expo-
sure defined as above. 
RESULTS 
We indentified 198 SE episodes (representing 71 % of 
279 episodes in our database), occurring in 167 patients, 
Epilepsia, 52(7):1292-1296, 2011 
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Table 2. Comparison of the groups of second-line treatment and the SE epileptîcus characteristics 
VPA PHT LEV Total 
N = 59 (29.8%) N = 70 (35.4%) N = 58 (29.3%) p-value (test) N = 187(%) 
Deadly etiology 15 (25.4%) 39 (55.7%) 34 (58.6%) <0.001 (x2) 88 (47.1%) 
Acute etiology 27(45.8%) 45 (64.3%) 39 (67.2%) 0.035 (x2) 111 (59.4%) 
STESS 23 26(44.1%) 49 (70.0%) 29 (50%) 0.007 (x2) 104(55.6%) 
Alertlconfus/somnolent 28 (47.5%) 23 (32.9%) 29(50%) 0.101 (x2) 70 (37.4%) 
Stupor/coma 31 (52.5%) 47 (67.1%) 29(50%) 0.101 {x2) 107 (57.2%) 
GCSE + NCSEC 22 (37.3%) 41 (58.6%) 17 (29.3%) 0.002 (x2) 80(42.8%) 
No previous seizure 24 (40.7%) 48 (68.6%) 30(51.7%) 0.006 (x2) 102 (54.5%) 
Age: mean (SD) 64(±18.9) 57.8(±18.1) 66.1 (±14.9) 0.02 (ANOVA) 62.4(±17.7) 
Failure of second-line treatment 15 (25.42%) 29 (41.42%) 28 (48.27%) 0.032 (/) 72 (38.5%) 
New morbidity or death at dis charge 25 (42.37%) 45 (64.28%) 39 (67.24%) 0.011 (x2) 109 (28.3%) 
Mortality/patients 4/48 (8.4%) 17/64 (26.6%) 9/47(19.1%) 0.045 (Fisher) 301159 ( 18.7%) 
GCSE, generalized convulsive status epilepticus; NCSE, nonconvulsive status epilepticus in coma; STESS, Status Epilepticus Severity Score; VPA, valproate; PHT, 
phenytoin; LEV, levetiracetam. 
during which benzodiazepines were followed by a second-
line agent. Only eight episodes (4%) lasted <30 min. 
Although in 11 episodes other oral agents were prescribed 
after failure of benzodiazepines (three received carbamaze-
pine, three pregabalin, two lamotrigine, two gabapentin, 
and one phenobarbital), analysis was restricted to the 187 
episodes in which PHT (70 episodes, 37%), VPA (59 epi-
sodes, 32%), or LEV (58 episodes, 31%) was used as sec-
ond-line agents. 
An overview of the treatment groups is presented in 
Table 2; several potentially important differences were 
observed. In the unadjusted analysis, patients treated with 
VPA had fewer unfavorable outcomes than the other two 
groups (failure of second-line agent, p = 0.032; new mor-
bidity or death, p = 0.011; mortality, p = 0.045). VPA 
failed to contrai the SE in 25.4%, PHT in 41.4%, and LEV 
in 48.3%. In the 11 subjects who received others agents, this 
corresponded to 28% (3/11). 
Patients with a deadly etiology (p < 0.001) and an acute 
etiology (p = 0.035) were more frequent in the LEV and 
PHT groups than in the VPA group, and subjects treated 
with VPA and LEV tended to have Jess severe SE episodes 
than patients of the PHT group (p = 0.007). The constitutive 
variables of the STESS (severe consciousness impairment, 
convulsive seizure, lack of previous seizures, higher age) 
were more frequently represented in the PHT group, except 
for age. Of note, treatment was started within an hour of 
symptoms onset in 48.5% of patients in the PHT, 30.5% in 
the VPA, and 29.5% in the LEV group (p = 0.03, chi-
square; the difference between VPA and LEV being not 
significant). Discrepancies in SE severity and etiology may 
have played a major role regarding the outcomes; therefore, 
a multivariable approach was applied. 
Logistic regression analyses were performed for the three 
outcomes, using VPA as the reference treatment (Table 3). 
AU models showed an acceptable to excellent goodness of 
fit (second-line treatment failure: p = 0.89; new morbidity 
Epi/epsia, 52(7):1292-1296, 2011 
doi: 10.11 ll/j .1528-1167.2011.03056.x 
Table 3. Deadly etiology, Status Epilepticus 
Severity Score (STESS) :::::3, PHT and LEV compared 
wîth VPA with logistic regression for the different 
outcomes: failure of second-li ne treatment; new 
morbidity or death; and mortality 
OR 95%CI p-Value 
Failure of second-li ne 
treatment 
Deadly etiology 0.997 0.53-1.89 0.995 
STESS23 1.51 0.8--2.85 0.201 
Treatment (refVPA) 
PHT as second line 1.88 0.85-4.14 0.119 
LEV as second line 2.69 1.19-6.08 0.017 
New morbidity or death 
at discharge 
Deadly etiology 3.92 1.97-7.88 <0.001 
STESS23 3.83 1.95-7.52 <0.001 
Treatment (refVPA) 
PHT as second line 1.35 0.6--3.02 0.463 
LEV as second line 1.98 0.86-4.57 0.109 
Mortality 
Deadly etiology 3.69 1.47-9.3 0.005 
STESS23 3.56 1.32-9.61 0.012 
Treatment (refVPA) 
PHT as second line 1.34 0.43-4.12 0.607 
LEV as second line 1.08 0.33-3.52 0.894 
STESS, Status Epilepticus Severity Score; VPA, valproate; PHT, phenytoin; 
LEV, levetiracetam. Bold type, statistically signifrcant values. 
or mortality: p = 0.38; mortality: p = 0.21). After adjust-
ments for SE severity and etiology, LEV was still related to 
a higher risk of second-Iine treatment failure as compared to 
VPA (OR 2.7, 95% CI 1.2-6.1). Treatment failures (PAF) 
attributable to the use of LEV corresponded to 16.8% (95% 
CI 6.0-31.4% ), suggesting that 16.8% of second-Iine medi-
cation failures might have been avoided using VP A instead 
of LEV. PHT did not differ significantly from the other two 
compounds. 
On the other side, the choice of the second-line treatment 
did not influence mortality and persistent morbidity at 
discharge (Table 3), whereas a STESS score :2:3 and a 
deadly etiology for the SE were strongly predictive for 
unfavorable outcome. 
DISCUSSION 
As opposed to the few comparative studies investigating 
the administration of VP A and PHT in SE (Misra et al., 
2006; Agarwal et al., 2007; Gilad et al., 2008), which 
despite several methodologic pitfalls suggest that these 
compounds are broadly comparable, LEV has not been 
tested against any other antiepileptic drug so far. This obser-
vational study suggests that the agent administered after 
benzodiazepines in patients with SE may influence the 
immediate treatment success, but not the outcome at hospital 
discharge: LEV seems to bear a higher risk of immediate treat-
ment failure as compared to VPA, with 16.8% of treatment 
failures attributable to LEV, with PHT being in between. 
It exists a paradox in the SE treatment, since practical and 
financial issues, and the position taken by regulatory author-
ities, render a prospective trial extremely difficult. A physi-
cian can choose among VPA, PHT, LEV, and even other 
compounds, in an almost complete absence of rational evi-
dence, but cannot collect information to determine efficacy 
without getting informed consent from the patient, which in 
an emergency condition is extremely difficult. In order to 
attenuate the lack of information in this field, we, therefore, 
used a sort of "natural experiment," analyzing the real-
world use ofthese compounds in SE and their efficacy, 
In this cohort, PHT was prescribed slightly more often as 
a second-line drug, probably because of the historical 
experience with this substance (Wallis et al., 1968; Pilz & 
Dreyer, 1969); however, VPA and LEV were each used in 
almost 30% of episodes. This likely reflects clinician's pref-
erences for these compounds in situations where local or 
cardiac toxicity of PHT (Craig, 2005), or the risk of pharma-
cokinetic interactions with PHT and VP A, might be at play 
(Knake et al., 2008). 
Although treatment success rates after VPA were higher 
as compared to PHT and LEV in the univariate analysis, 
only the difference between VPA and LEV persisted after 
adjustment for etiology and SE severity (including age), two 
major predictors of SE outcome (Towne et al., 1994; 
Logroscino et al., 1997). Interestingly, the success rate 
among the 11 patients treated with other compounds was 
similar to that of VP A. It is unlikely that the observed differ-
ences resulted from systematic discrepancies in the loading 
or maintenance dosage of the second-line compounds. 
Actually, VPA was rather low-dosed in our hospital as 
compared to other series (Misra et al., 2006) and the most 
recent European guidelines (Meierkord et al., 2010), 
whereas PHT was given as recommended by the European 
guidelines (Meierkord et al., 2010); LEV was administered 
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as previously reported in other centers (Knake et al., 2008; 
Benung et al., 2009) and the European guidelines (Meierkord 
et al., 2010), where loading doses of at least 1,000 mg and 
maintenance doses of about 2,000 mg are described. Fur-
thermore, escalating LEV dosage beyond 3,000 mg/day has 
not been shown to provide any additional benefit (Rossetti 
& Bromfield, 2006). The fact that LEV was given orally in 
few subjects before its intravenous availability (June 2007) 
may theoretically have slowed its action; however, this 
occurred in only two patients, and they responded to the 
treatment. In fact, previous reports describe a definite effect 
after oral administration in SE (Rossetti & Bromfield, 
2006). 
STESS and deadly etiology were robust predictors for 
outcome at discharge, independently of the type of second-
line treatment. This reflects convergent information from 
several studies (Towne et al., 1994; Logroscino et al., 1997; 
Rossetti et al., 2006), and suggests that various factors 
contribute to SE prognosis more than the specific antiepi-
leptic therapy. In fact, differences in immediate SE control 
following the second-line drug might be "compensated" by 
the subsequent agent, suggesting that if the SE episode is 
per se treatable, it will respond to another drug. Again, it is 
tempting to assume that the biologie background represents 
the major prognostic determinant (Towne et al., 1994; 
Rossetti et al., 2006). 
Our study has some limitations. Although we used a pro-
spective database, data analysis was performed retrospec-
tively for the purpose of this evaluation, and the treatment 
allocation was not randomized; therefore, we cannot 
exclude confounding factors. However, multivariable anal-
yses were used to control for the most important known out-
come predictors, including the STESS and the etiology; 
moreover, there was no significant difference in treatment 
delay between VPA and LEV. Less important predictors 
could not be assessed. These include adequacy of initial 
treatment with benzodiazepines, duration of SE, and timing 
of administration of second-line drugs. We did not specifi-
cally assess missed patients from the registry, but since in 
our hospital ail subjects with a first seizure or SE suspicion 
have a neurologie consultation and an EEG, it is relatively 
unlikely that problems with case ascertainment had major 
influence on the results of this study. In our database, a 
second-line treatment was given more frequently (198/279 
episodes -= 70%) as compared to the first-line failure rates 
in published trials [35% for lorazepam (Lowenstein & 
Alldredge, 1998), 40% for lorazepam and 57% for diazepam 
(Alldredge et al., 2001), and 22% for lorazepam and 42% 
for diazepam (Leppik et al., 1983)]. We believe that several 
patients received a second-line agent shortly after ben-
zodiazepines to prevent seizure recurrence (as it is com-
monly performed in clinical practice), leading to an 
overestimation of the efficacy of the three treatments. This 
reflects broadly used common practice (persona! communi-
cations with several European and American SE special-
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ists), and differs from the semiartificial trial settings. How-
ever, it is unlikely that a specific second-line agent was 
administered in case of "almost controlled" SE, generating 
a systematic bias. Furthermore, two senior epileptologists 
oversaw most of the treatment strategies, rendering unlikely 
a prescription bias by different physicians. The fact that in 
our series both PHT and VPA appeared less efficacious than 
previously reported (Agarwal et al., 2007) probably reflects 
a different etiologic and demographical profile (India vs. 
Switzerland). Finally, unfortunately our database does not 
allow extrapolating any estimation of specific side-effects 
related to the analyzed treatments, nor to retrieve specific 
drug dosages. 
In conclusion, this study, which to the best of our knowl-
edge represents the first comparison between PHT, VPA, 
and LEV in SE, suggests some caution in the use of LEV in 
this setting, pending a well-designed comparative trial. 
Despite several putative difficulties in patients' recruitment 
and organization, this approach appears clearly necessary to 
clarify this situation. 
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SUMMARY 
Status epilepticus (SE) is associated with significant mor-
tality and morbidity. A reliable prognosis may help better 
manage medical resources and treatment strategies. We 
examined the role of preexisting comorbidities on the 
outcome of patients with SE, an aspect that has received 
little attention to date. We prospectively studied incident 
SE episodes in 280 adults occurring over 55 months in our 
tertiary care hospital, excluding patients with postanoxic 
encephalopathy. Different models predicting mortality 
and return to clinical baseline at hospital discharge were 
compared, which included demographics, SE etiology, a 
validated clinical Status Epilepticus Severity Score 
(STESS), and comorbidities (assessed with the Charlson 
Comorbidity Index) as independent variables. The overall 
short-term mortality was 14%, and only half of patients 
Status epilepticus (SE) represents a severe medical condi-
tion (Neligan & Shorvon, 2011); some independentpredictors 
of dismal outcome have been identified, such as acute or 
potentially fatal etiology, advanced age, de novo presentation, 
and impairment of consciousness before treatment (Towne 
et al., 1994; Logroscino et al., 1997; Rossetti et al., 2006). 
However, these variables encompass only a limited aspect of 
the clinical background. In fact, the role of previously existing 
medical problems has received far Jess attention. 
We undertook this analysis to investigate how comorbidi-
ties influence SE outcome in addition to other known 
predictors. 
METHODS 
Patients and procedures 
We analyzed a prospective registry including ail adult 
patients (16 years and older) with SE admitted to our ter-
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returned to their clinical baseline. On bivariate analyses, 
age, STESS, potentially fatal etiologies, and number of 
preexisting comorbidities were all significant predictors 
of both mortality and return to clinical baseline. As com-
pared with the simplest predictive model (including 
demographics and deadly etiology), adding SE severity 
and comorbidities resulted in an improved predictive per-
formance (C statistics 0.84 vs. O. 77 for mortality, and 0.86 
vs. 0.82. for return to clinical baseline); comorbidities, 
however, were not independently related to outcome. 
Considering comorbidities and clinical presentation, in 
addition to age and etiology, slightly improves the predic-
tion of SE outcome with respect to both survival and func-
tional status. This analysis also emphasizes the robust 
predictive role of etiology and age. 
KEY WOR.DS: Predictors, Charlson Comorbidity Index, 
Prognosis, Etiology, Age. 
tiary hospital between April 1, 2006 and October 31, 2010 
(55 months). Details may be found elsewhere (Novy et al., 
2010). Briefly, SE was defined as the continuous occurrence 
of seizures for >30 min (until 2008), and 5 min (since 
2008), as suggested by the operational definition (Lowen-
stein et al., 1999). Seizures were diagnosed clinically, but 
electroencephalography (EEG) confirmation (at least 
20-min recordings with background reactivity evaluation) 
was required for nonconvulsive events. SE episodes were 
identified by the neurologie consultants at our emergency 
and intensive care units, and by the EEG medical staff. 
Patients with postanoxic SE were not included in the cohort. 
Only incident cases were considered, to allow every SE epi-
sode an equal chance to reach ail possible outcomes. This 
study was approved by our ethics commission. 
Variables 
Demographics, history of previous seizures, worst 
seizures type, level of consciousness before treatment, 
pharmacologie treatments, and SE etiology were recorded 
prospectively. The Status Epilepticus Severity Score 
(STESS), a validated SE clinical severity score, including 
age, history of previous seizures, seizure type, and con-
sciousness was calculated (0-6 points) (Rossetti et al., 
2008) (Table SI) and categorized in ~3 (bad outcome 
e89 
e90 
prediction) versus <3 (good outcome prediction). Etiology 
was considered "potentially fatal" if potentially leading to 
death and not specifically treated, as described previously 
(Rossetti et al., 2006). 
The Charlson Comorbidity Index (CCI), a validated score 
of 19 different medical conditions (Table S2), was used to 
assess the comorbidities (Charlson et al., 1987). CCI was 
calculated after discharge, based on the medical files, by 
identification of ail comorbid conditions present on admis-
sion (except SE etiology). The CCI was categorized in three 
groups: CCI = 0, CCI = 1-2, and CCI ;:::3; in addition, we 
analyzed every medical condition as an individual variable. 
The clinical condition at hospital discharge represented the 
primary outcome; information on clinical condition was 
obtained prospectively and categorized into return to clini-
cal baseline (premorbid functional and neurologie status), 
new impairment or death. 
Statistical analyses 
Potential predictors were analyzed for their relationship 
with the outcomes "return to baseline" and "mortality" 
using chi-square (/) tests. Stepwise logistic regressions 
were performed to generate predictive models using poten-
tial predictors, including demographics, SE severity, etiol-
ogy, and comorbidities. Age was dichotomized at 65 years; 
of note, because the STESS includes age, the latter was 
omitted in models considering this score. Discrimination 
power was assessed using the C statistics and 95% confi-
dence intervals (Cis), and goodness of fit with the Hosmer-
Lemeshow / test; the Akaike Information Criterion (AIC) 
and Bayesian Information Criterion (BIC) values were used 
as a rough comparison of the models among them, whereas 
forma! comparisons among receiver operating characteristic 
(ROC) curves were pe1formed using a nonparametric 
approach. For multiple comparisons, we conservatively 
applied Bonferroni corrections to obtain a global p < 0.05. 
Analyses were performed with version 9 of the Stata soft-
ware (StataCorp, College Station, TX, U.S.A.). 
RESULTS 
Arnong 335 SE events recorded during the study period, 
we indentified 280 incident episodes. Demographics and 
most relevant clinical variables of the cohort are illustrated 
in Table 1. Twenty episodes (7%) lasted between 5 and 
29 min. Gender was evenly distributed, the mean age 
(± standard deviation [SD]) was 59.3 (±18.5) years, and 
59% of patients had a de novo SE episode. Slightly more 
than one half of the patients displayed a severely impaired 
consciousness (only 2.5% had a nonconvulsive status epi-
lepticus in coma), or potentially fatal SE etiologies. Among 
the most frequent causes, 13.9% of SE were symptomatic of 
primary brain tumor or meningioma, 12.9% had a central 
nervous system hemorrhage, 9.7% were symptomatic of an 
old stroke; and 9.6% had a cryptogenic SE. In 55.4% of 
Epilepsia. 53(5):e89-e92, 2012 
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patients a severe SE was retained (STESS ;:::3); 10.7% of 
patients received coma induction for SE treatment. About 
one-third of patients did not have any prior comorbidity, 
whereas one-third had a moderate, and the last third pre-
sented a high comorbidity index. 
The overall short-term mortality was 14%, and only half 
of patients returned to baseline conditions at hospital dis-
charge. Bivariate analyses demonstrated that age, STESS, 
potentially fatal etiologies, and an increased number of 
comorbidities were significant predictors of both outcomes, 
whereas gender was not (for more details, see Table S3). 
With respect to in-hospital mortality, calibrations for ail 
models were acceptable and are illustrated in Fig. lA; the 
comparison of the six models did not show any statistically 
significant difference (p = 0.1325, /) (for more details 
about model's calibration, see Table S4A). Pairwise analy-
ses were performed using p < 0.017 (according to the Bon-
ferroni's correction: 0.05/3) as a significant threshold. 
Compared to the simplest model (model 0), the model 
including the STESS (model 1, p = 0.166, /) and the best 
model including CCI (mode! 3, p = 0.064, /) were not sta-
Table 1. Tertiary care hospital SE patients' 
demographics and clinical characteristics 
Number (proportion) 
Demographic data 
Gender (male) 139 (49.6%) 
Age(SD) 59.3 (18.5) 
Presence of previous seizures 115 (41%) 
Severe conscious impairment 159 (56%) 
(stuporous or comatose) before treatment 
Deadly etiology 129(46%) 
STESS23 155 (55.4%) 
Coma induction for SE treatment 30 (10.7%) 
Charlson Comorbidity Score(%) 
0 75 (26.8) 
1 or2 1 OO (35.7) 
23 105 (35.5) 
Comorbidities (according to 
Charlson et al., 1987) (%) 
Cerebrovascular disease 61 (21.8) 
Anytumor 58 (20.7) 
Chronic pulmonary disease 31 (11) 
Solid metastatic tumor 31 (11) 
Congestive heart disease 25 (8.9) 
Moderate/severe renal disease 23 (8.2) 
Dementia 22 (7.9) 
Myoca•dial infarction 21 (7.5) 
Peptic ulcer 21 (7.5) 
Peripheral vascular disease 18 (6.4) 
Hemiplegia 16 (5.7) 
Moderate/severe liver disease 14 (5) 
Mild liver disease 11 (3.9) 
Diabetes 9 (3.2) 
HIV 6 (2.1) 
Connective tissue disease 4 (1.4) 
Lymphoma 4 (1.4) 
Diabetes with organ damage 2 (0.7) 
Leukemia 2 (0.7) 
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Figure 1. 
Comparison of six predictive models (with model's construc-
tion). (A) For the outcome " mortality": mode/ 0: Gender, age, 
potentially fatal etiology; mode/ I: Gender, potentially fatal 
etiology, STESS; mode/ 2: Gender, age, potentially fatal etiology, 
categorized CCI; mode/ 3: Gender, age, potentially fatal etiol-
ogy, each variable of CCI; mode/ 4: Gender, potentially fatal 
etiology, STESS, categorized CCI; mode/ 5: Gender, potentially 
fatal etiology, STESS, each variable of CCI. (B) For the outcome 
"Return to base line": mode/ OO: Gender, age, potentially fatal 
etiology; mode/ 11: Gender, potentially fatal etiology, STESS; 
mode/ / 2: Gender, age, potentially fatal etiology, categorized 
CCI; mode/ 13: Gender, age, potentially fatal etiology, each vari-
able of CCI; mode/ 14: Gender, potentially fatal etiology, STESS, 
categorized CCI; mode/ 15: Gender, potentially fatal etiology, 
STESS, each variable of CCI. 
Epilepsia © ILAE 
tistically different. The mode) including both STESS and 
CCI was better (mode) 5, p = 0.0158, /)as showed a slight 
improvement of the ROC curve area (0.77 vs. 0.84). 
We used a si mi Jar approach for retum to baseline clinical 
condition (Fig. IB). Ali models ' calibrations were accept-
e91 
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able, except for mode) 15 (for more details about model's 
calibration, see Table S4B). The comparison of the six mod-
els indicated some heterogeneity (p = 0.0403, /). The best 
mode), including CCI (mode) 13), was better than the sim-
plest mode) (model OO, p = 0.0043, /) , corresponding to a 
modest improvement of the ROC curve area (0.82 vs. 0.86). 
To summarize, the best predictive models included 
etiology, STESS, and each variable of the CCI for mortality 
(mode) 5) , and demographics, etiology, and each variable 
of the CCI for retum to clinical baseline conditions 
(model 13). 
DISCUSSION 
This study shows that medicat comorbidities increase rel-
atively marginally the prediction accuracy of SE outcome, 
and confirms that age and etiology are robust outcome prog-
nosticators in this setting. 
Our results are in tine with those of previous studies per-
formed on different cohorts (Towne et al. , 1994; Logroscino 
et al. , 1997; Rossetti et al. , 2006) that identified age and SE 
etiology as the main independent outcome predictors. In 
addition, one recent work suggested that patients with a 
higher number of comorbid conditions have a worse out-
come (Koubeissi & Alshekhlee, 2007). However, this large 
data-based study, focused on convulsive SE, has important 
limitations: Its design included a retrospective identification 
of subjects with SE, and assessment of their comorbidities 
was based on International Classification of Diseases (ICD) 
diagnoses (Rossetti & Logroscino, 2008). Furthermore, the 
short-term mortality of 3% seems unusually tow in this 
clinicat setting, and concomitant medical diagnoses were 
identified only as independent prognostic factors , without 
any specific analysis addressing their added value in prog-
nostic models including other major predictors. 
Regarding etiology, because SE is often one of the clini-
cat manifestations of brain injury, it seems Jogical that the 
nature of that injury will markedly influence prognosis. 
Massive and irreversibte damage predicts perse a devastat-
ing outcome, whereas reversibte conditions such as anticon-
vulsant drug withdrawal may herald a more favorable 
outcome after SE. As outlined previously (Rossetti et al., 
2006; Novy et al. , 2010), "acute etiologies" are Jess robust 
in predicting outcome than " potentially fatal " etiotogies; 
this may be related to the fact that the latter encompass those 
acute and progressive symptomatic etiologies that are more 
dangerous for the patient. 
Our study is limited to a hospital-based cohort, but since 
SE represents a condition that is predominantly treated al 
hospitals, this aspect should not affect our results. The sec-
ond limitation lies in the fact that we investigated only the 
effect of comorbidities on prognosis at hospital discharge, 
but we cannot exclude that long-term prognosis may be 
influenced by comorbidities. The strength of our study 
builds on its prospective design, and the use of clearly 
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defined inclusion criteria. Our mortality rate (14% ), which 
is in the middle range of population-based assessments in 
Europe and the United States over the last two decades~ 7% 
(Coeytaux et al., 2000) and 22% (DeLorenzo et al., 
1996)---corroborates our findings. Finally, any score may 
not reflect exactly the clinical background of a patient, but 
because the CCI is widely used and validated, it seems to be 
a reasonable choice to represent patient's comorbidities. 
In conclusion, comorbidities and the clinical presentation 
seem to affect the outcome of SE in a relatively marginal 
way, whereas age and etiology appear as robust and widely 
applicable predictors. This emphasizes the importance of a 
thorough search for the underl ying cause of SE in the clinical 
setting. In addition, because the presence of comorbidities 
does not necessarily predict a bad outcome, this should not 
dissuade physicians from treating patients with SE and 
comorbid conditions appropriately. Obviously, comorbidities 
are important regarding contraindications and side effects of 
antiepileptic drugs. In this regard they may influence the out-
come by influencing the utilization of specific treatments. 
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Please note: Wiley-Blackwell is not responsible for the 
content or functionality of any supporting information sup-
plied by the authors. Any queries (other than missing mate-
rial) should be directed to the corresponding author for the 
article. 
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Supporting information: 
Table 51: Status Epilepticus Severity Score {STESS), a favorable score is 0-2. Adapted from Rossetti et al., 
2008a 
Consciousness 
Worst seizure type 
Age 
Features 
Alert or somnolent/confused 
Stuporous or comatose 
Simple-partial, complex-partial, absence, 
myoclonic* 
Generalized-convulsive 
Nonconvulsive status epilepticus in coma 
< 65 years 
~ 65 years 
History of previous seizures Yes 
No or unknown 
Total 
* complicating idiopathie generalized epilepsy 
Table 52: Charlson Comorbidity Index. Adapted from Charlson et al., 1987 
Assigned weights for diseases 
1 
2 
3 
6 
Conditions 
Myocardial infarct 
Congestive heart failure 
Peripheric vascular disease 
Cerebrovascular disease 
Dementia 
Chronic pulmonary disease 
Connective tissue disease 
Ulcer disease 
Mild liver disease 
Diabetes 
Hemiplegia 
Moderate or severe renal disease 
Diabetes with end organ damage 
Any tumor (incl.): 
• Leukemia 
• Lymphoma 
Moderate or severe liver disease 
Metastatic solid tumor 
AIDS 
5TE55 
0 
1 
0 
1 
2 
0 
2 
0 
1 
0-6 
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MODELS 
Model 0 : Gender. age. potentially fatal etiology 
Mode! 1 : Gender. potentially fatal etiology. 
STE SS 
Modez 2 : Gender. age, potentially fatal etiology, 
categorized Charlson CoDlorbidity Index 
11.fodel 3 : Gender. age. pctentially fatal etiology, 
each variable of Charlson Comorbidity Index 
Model 4 : Gender. potentially fatal etiology, 
STESS, categorized Charlson Comorbidity Index 
1lfodel 5: Gender. potentially fatal etiology, 
STESS. each variable of Charlson Comorbidity 
Index 
ModeldiscriJJlination 
l C-statistic (95% CI) 1 
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MODELS 
Mode! OO : Gender, age, potentially fatal etiology 
Mode! 11: Gender, potentially fatal etiology, 
STE SS 
Mode/ 12: Gender, age, potentially fatal etiology, 
categorized Charlson Comorbidity Index 
Modeï 13: Gender, age, potentially fatal etiology, 
each variable of Charlson Comorbidity Index 
Mode/ 14: Gender, potentially fatal etiology, 
STESS, categorized Charlson Comorbidity Index 
Mode! 15: Gender, potentially fatal etiology, 
STESS, each variable of Charlson Comorbidity 
Index 
Model discrimination Model calibration 
1
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Model comparisons 
1 AIC BIC 
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